177 related articles for article (PubMed ID: 17693582)
21. Adaptor protein Lnk associates with Tyr(568) in c-Kit.
Gueller S; Gery S; Nowak V; Liu L; Serve H; Koeffler HP
Biochem J; 2008 Oct; 415(2):241-5. PubMed ID: 18588518
[TBL] [Abstract][Full Text] [Related]
22. The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders.
Maslah N; Cassinat B; Verger E; Kiladjian JJ; Velazquez L
Leukemia; 2017 Aug; 31(8):1661-1670. PubMed ID: 28484264
[TBL] [Abstract][Full Text] [Related]
23. [Role of LNK gene mutation in pathogenesis of myeloproliferative neoplasms-review].
Chen Y; Wu XQ; Han CS; Zhu P; Wei JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1309-12. PubMed ID: 24156456
[TBL] [Abstract][Full Text] [Related]
24. Role of the adaptor protein LNK in normal and malignant hematopoiesis.
Gery S; Koeffler HP
Oncogene; 2013 Jun; 32(26):3111-8. PubMed ID: 23045270
[TBL] [Abstract][Full Text] [Related]
25. MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.
Ma W; Zhang X; Wang X; Zhang Z; Yeh CH; Uyeji J; Albitar M
Diagn Mol Pathol; 2011 Mar; 20(1):34-9. PubMed ID: 21326037
[TBL] [Abstract][Full Text] [Related]
26. The BRISC deubiquitinating enzyme complex limits hematopoietic stem cell expansion by regulating JAK2 K63-ubiquitination.
Donaghy R; Han X; Rozenova K; Lv K; Jiang Q; Doepner M; Greenberg RA; Tong W
Blood; 2019 Apr; 133(14):1560-1571. PubMed ID: 30755420
[TBL] [Abstract][Full Text] [Related]
27. The adaptor Lnk (SH2B3): an emerging regulator in vascular cells and a link between immune and inflammatory signaling.
Devallière J; Charreau B
Biochem Pharmacol; 2011 Nov; 82(10):1391-402. PubMed ID: 21723852
[TBL] [Abstract][Full Text] [Related]
28. Lnk constrains myeloproliferative diseases in mice.
Bersenev A; Wu C; Balcerek J; Jing J; Kundu M; Blobel GA; Chikwava KR; Tong W
J Clin Invest; 2010 Jun; 120(6):2058-69. PubMed ID: 20458146
[TBL] [Abstract][Full Text] [Related]
29. [MPLW515L point mutation in patients with myeloproliferative disease].
Xia J; Xu W; Zhang SJ; Fan L; Qiao C; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1421-4. PubMed ID: 19099657
[TBL] [Abstract][Full Text] [Related]
30. Lnk negatively regulates self-renewal of hematopoietic stem cells by modifying thrombopoietin-mediated signal transduction.
Seita J; Ema H; Ooehara J; Yamazaki S; Tadokoro Y; Yamasaki A; Eto K; Takaki S; Takatsu K; Nakauchi H
Proc Natl Acad Sci U S A; 2007 Feb; 104(7):2349-54. PubMed ID: 17284614
[TBL] [Abstract][Full Text] [Related]
31. Phosphorylated c-Mpl tyrosine 591 regulates thrombopoietin-induced signaling.
Sangkhae V; Saur SJ; Kaushansky A; Kaushansky K; Hitchcock IS
Exp Hematol; 2014 Jun; 42(6):477-86.e4. PubMed ID: 24607955
[TBL] [Abstract][Full Text] [Related]
32. JAK and MPL mutations in myeloid malignancies.
Tefferi A
Leuk Lymphoma; 2008 Mar; 49(3):388-97. PubMed ID: 18297515
[TBL] [Abstract][Full Text] [Related]
33. Regulation of hematopoietic development in the aorta-gonad-mesonephros region mediated by Lnk adaptor protein.
Nobuhisa I; Takizawa M; Takaki S; Inoue H; Okita K; Ueno M; Takatsu K; Taga T
Mol Cell Biol; 2003 Dec; 23(23):8486-94. PubMed ID: 14612394
[TBL] [Abstract][Full Text] [Related]
34. [Expression of JAK2V617F and MPLW515L/K mutation in 30 suspected cases of early myeloproliferative disorders].
Fan Z; Zhang R; Shen YM; Fei HR; Zhu ZL; Cen JN
Zhonghua Xue Ye Xue Za Zhi; 2008 Sep; 29(9):611-4. PubMed ID: 19175989
[TBL] [Abstract][Full Text] [Related]
35. SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F.
Koren-Michowitz M; Gery S; Tabayashi T; Lin D; Alvarez R; Nagler A; Koeffler HP
Br J Haematol; 2013 Jun; 161(6):811-20. PubMed ID: 23590807
[TBL] [Abstract][Full Text] [Related]
36. LNK/SH2B3 Loss of Function Promotes Atherosclerosis and Thrombosis.
Wang W; Tang Y; Wang Y; Tascau L; Balcerek J; Tong W; Levine RL; Welch C; Tall AR; Wang N
Circ Res; 2016 Sep; 119(6):e91-e103. PubMed ID: 27430239
[TBL] [Abstract][Full Text] [Related]
37. Two activating mutations of MPL in triple-negative myeloproliferative neoplasms.
Xie J; Chen X; Gao F; Hou R; Tian T; Zhang Y; Fan L; Hu J; Zhu G; Yang W; Wang H
Cancer Med; 2019 Sep; 8(11):5254-5263. PubMed ID: 31294534
[TBL] [Abstract][Full Text] [Related]
38. The Lnk adaptor protein: a key regulator of normal and pathological hematopoiesis.
Velazquez L
Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):415-29. PubMed ID: 22990499
[TBL] [Abstract][Full Text] [Related]
39. A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction.
Pancrazzi A; Guglielmelli P; Ponziani V; Bergamaschi G; Bosi A; Barosi G; Vannucchi AM
J Mol Diagn; 2008 Sep; 10(5):435-41. PubMed ID: 18669880
[TBL] [Abstract][Full Text] [Related]
40. Identification and characterization of an alternative splice variant of Mpl with a high affinity for TPO and its activation of ERK1/2 signaling.
Wang Q; Sun R; Wu L; Huang J; Wang P; Yuan H; Qiu F; Xu X; Wu D; Yu Y; Liu X; Zhang Q
Int J Biochem Cell Biol; 2013 Dec; 45(12):2852-63. PubMed ID: 24144576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
